RapidEye
Individualized cancer vaccines and antibody-drug conjugates will be among the dominant biotech innovations in cancer next year, with key trial readouts expected from companies including Moderna (NASDAQ:MRNA), Merck (NYSE:MRK), and AstraZeneca (AZN), according to a